News | July 06, 2024
Biogen completes acquisition of HI-Bio
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Subscribe To Our Newsletter & Stay Updated
